Why better change communication matters for Talking Medicines’ workplace positioning

Tern plc

Talking Medicines is using a familiar workplace challenge to sharpen the case for its employee insight offering. In its latest commentary on change communication, the company focuses on a problem that remains highly relevant for employers: as organisations move through repeated rounds of transformation, the volume of internal messaging rises, but clarity does not always keep pace.

New technologies, changing work models and shifting business priorities are creating an environment in which employees are regularly asked to adapt. Against that backdrop, Talking Medicines argues that communication has become a critical management function, not simply an administrative task.

It places the company’s PeopleVoice proposition in a category linked to execution risk inside large organisations. If change programmes are poorly understood, businesses can face slower adoption, weaker engagement and reduced confidence among staff. By aligning its offer with that pressure point, Talking Medicines is presenting its technology as part of the infrastructure needed to support organisational change more effectively.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search